Cancer Peptide Vaccine FTIH
Research type
Research Study
Full title
Open-label, phase 1 study of S-488210/S-488211 to evaluate the safety and tolerability in patients with unresectable recurrent and/or metastatic solid tumor
IRAS ID
258992
Contact name
Mark Linch
Contact email
Sponsor organisation
Shionogi Ltd
Eudract number
2018-002566-38
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
The purpose of this study is to see if S-488210/S-488211 is safe and able to hopefully strengthen your immune system to respond to a cancer treatment in patients who have solid tumors. Before participating in this study, patients will have received the standard of care treatments and their disease will have progressed. S-488210/S-488211 is an experimental drug (a “cancer peptide vaccine”). “Experimental” means that the drug is still being tested and has not been approved for use by regulatory authorities (for example, UK Medicines and Healthcare products Regulatory Agency, the Pharmaceuticals and Medical Devices Agency [Japan], the US Food and Drug Administration, the European Medicines Agency, and other country authorities).
REC name
London - City & East Research Ethics Committee
REC reference
19/LO/0101
Date of REC Opinion
13 Mar 2019
REC opinion
Further Information Favourable Opinion